Leerink Swann Initiates Coverage on Incyte Corp (INCY) with an Outperform; Street Under-Appreciating Potential
More News related to INCY
- Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
- Monness, Crespi, Hardt Initiates Coverage on Incyte (INCY) with a Buy
- Incyte Announces Redemption of Its 31/2% Convertible Senior Notes Due 2011 and Its 31/2% Convertible Subordinated Notes Due 2011
- Notable Analyst Rating Changes 1/15: AMD, NRG, K, OMX, PRIM Upgraded; TOL, INCY, AYR, CTCM, PAYX Downgraded
- UBS Downgrades Incyte (INCY) to Neutral
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Leerink Swann initiates coverage on Incyte Corp (Nasdaq: INCY) with an Outperform rating.
Leerink analyst says, "We believe the Street is under-appreciating the commercial potential for INCY's JAK-inhibitor franchise, particularly topical INCB18424, which we see as INCY's lowest-risk development program with a sizable potential market opportunity in both psoriasis and other topical inflammatory indications. Significant upside should also be driven by INCB18424 in myeloproliferative disorders and INCB28050 in inflammatory disorders. We view INCY shares as fairly valued on a risk-adjusted, fully diluted basis in the $15-17/share range."
To see more analyst ratings on INCY Click Here.
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.
Related Categories
New CoverageStocks Mentioned
+0.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
